Adagene

Redefining the design and discovery of therapeutic antibodies #LifeIsMotion

[Adagene @AdageneGlobal]

Welcoming Peter Lebowitz, MD, PhD, to Adagene’s Scientific & Strategic Advisory Board.
A seasoned oncology R&D leader from discovery to commercialization.
He will help advance ADG126 via our SAFEbody® platform in MSS CRC.
Excited for what’s ahead.
🔗https://t.co/VnV7qWvgNV

[Adagene @AdageneGlobal]

We're pleased to announce the closing of our $70 million public offering of American Depositary Shares. These funds will support advancement of our novel antibody-based cancer immunotherapies.
#ImmunoOncology

[Adagene @AdageneGlobal]

We are thrilled to announce a clinical collaboration with @Incyte to evaluate the combination of our anti-CTLA-4 SAFEbody® technology & Incyte’s TGFβR2 × PD-1 bispecific antibody in patients with MSS CRC with or without liver metastases.
https://t.co/YbpCB9d60v
#ImmunoOncology

[Adagene @AdageneGlobal]

Results showed improved durability of response, long-tail survival typical of CTLA-4 immunotherapy, low 4% overall discontinuation rate and a favorable safety profile.
https://t.co/82idYmKv2r
#ImmunoOncology

[Adagene @AdageneGlobal]

We are pleased to share updated data from the Phase 1b/2 study of muzastotug in combination with KEYTRUDA® (pembrolizumab) in patients with advanced MSS CRC with no liver metastases.
https://t.co/82idYmKv2r

[Adagene @AdageneGlobal]

Season’s greetings and best wishes to everyone.
Grateful for the momentum we’ve built and excited to keep pushing forward—riding the fast track into the year ahead.

[Adagene @AdageneGlobal]

FDA Fast Track designation for muzastotug + KEYTRUDA® is a significant step forward for patients with MSS mCRC and a strong endorsement of our mission to deliver safer, more effective immunotherapy.
Learn more: https://t.co/Q5BJEPmExe
#Adagene #Muzastotug #CTLA4 #FastTrack

[Adagene @AdageneGlobal]

We are excited to announce a licensing agreement that enables Third Arc Bio to utilize Adagene’s SAFEbody® technology platform to generate masked CD3 T cell engagers targeting unique tumor-associated antigens.
Learn more:https://t.co/KzwBeWoBtF
#ImmunoOncology #SAFEbody

[Adagene @AdageneGlobal]

🚀 Adagene amends its collaboration with Exelixis to develop a 3rd SAFEbody™ ADC for a solid tumor target.
Adagene is eligible for milestones & royalties under this amendment.
🔗 Read more: https://t.co/l672EueKKp

#Oncology #ADC #SAFEbody

[Adagene @AdageneGlobal]

Tomorrow! Join Adagene’s Chief Strategy Officer, Mickael Chane-Du, at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
📅 Date: Wednesday, September 10
⏰ Time: 7:00 AM ET
👉 Join live or watch the replay here: https://t.co/84CEbJMW7Q

[Adagene @AdageneGlobal]

Thrilled to welcome Dr. Axel Hoos to Adagene’s Executive Advisory team! Together, we look forward to shaping the future of precision Immuno-Oncology.
https://t.co/FWpsDIpO9n
#ImmunoOncology #ADG126

[Adagene @AdageneGlobal]

We’re pleased to share our strong progress in H1 2025: ADG126 mOS 19.4m in MSS CRC, FDA P2/P3 alignment, $25M Sanofi investment & new ADC partnership.
Details 👉 https://t.co/mJoaPGLXYd
#ADAG #ADG126

[Adagene @AdageneGlobal]

Adagene announces positive FDA feedback on its clinical development plan for Muzastotug (ADG126) in MSS colorectal cancer following a productive Type B meeting.
🔗 Read more: https://t.co/YfWDKBqPHB

[Adagene @AdageneGlobal]

We’re partnering with ConjugateBio to develop novel bispecific ADCs using Adagene’s proprietary technology— a big step forward in advancing safer, more targeted cancer therapies.
https://t.co/mgtcl7m051
#Adagene #ADC #CancerTherapy #Biotech #SAFEbody

[Adagene @AdageneGlobal]

We are thrilled to announce the expansion of our partnership with @sanofi, highlighting the potential of our SAFEbody platform and the clinical proof of concept for ADG126, our masked anti-CTLA-4 program.Learn more: https://t.co/8a1XR9vUQt
#CTLA4 #ColorectalCancer

[Adagene @AdageneGlobal]

We announced updated data being presented at #ASCO25 from our Phase 1b/2 study in advanced microsatellite stable #colorectalcancer, with muzastotug (ADG126) showing a 29% confirmed ORR when added to pembrolizumab (KEYTRUDA®).
Learn more:https://t.co/hBbaGpQkbo

[Adagene @AdageneGlobal]

Don't miss Dr. Peter Luo, Adagene CEO, presenting "Breakthrough Immunotherapy in MSS CRC: Novel Mechanism, Modality, and Dosing Drive 33% Confirmed ORR in Phase 1b/2 Trial" at the Stifel 2025 Virtual Targeted Oncology Forum.
Join live here: https://t.co/xmNaH9mPMd

[Adagene @AdageneGlobal]

Join us for a virtual KOL event on Sat, Jan. 25 at 1pm ET with Aurélien Marabelle, MD, PhD, Daneng Li, MD, and Marwan G. Fakih, MD, to discuss the current treatment landscape for patients with advanced/metastatic MSS CRC. Register: https://t.co/SPsJgLF5PT

[Adagene @AdageneGlobal]

Honoring #AdaLovelace: a trailblazer in math & computing who inspires Adagene’s mission to redefine #cancer treatment through AI-driven antibody design. Her brilliance drives us to create safer, effective therapies like ADG126 SAFEbody, offering hope to MSS CRC patients.

[Adagene @AdageneGlobal]

We loved Dr. Aurelien Marabelle’s talk @sitcancer 2024 on CTLA-4-mediated Treg depletion, highlighting the CTLA-4 + PD-1 combo’s benefits across cancer types. He reinforced the value of early immunotherapy & its impact on MSS CRC. Learn about ADG126: https://t.co/T3nlQqxFCL